title: Cost-effectiveness of lanreotide Autogel in treatment algorithms of acromegaly.
abstract: The introduction of effective pharmacological treatments has changed the management of acromegaly. However, chronic, life-long treatment with somatostatin analogues and/or growth hormone receptor antagonists is very expensive. We estimated the costs of treatment algorithms to control acromegaly from a Dutch perspective. We used the following assumptions: after the diagnosis of acromegaly there is a mean remaining lifespan of approximately 33 years; the success rates of surgery and somatostatin analogues in controlling the disease are approximately 60%; and the lifelong costs of different algorithms to control acromegaly in 100 patients ranged from 43 million euros (primary surgery and secondary somatostatin analogues) to 57 million euros (primary somatostatin analogues and secondary surgery) and even reached 95 million euros (medical treatment only). In algorithms that include trans-sphenoidal surgery, the lifetime treatment costs are almost 46-59% cheaper per 100 patients than in algorithms with medical treatment but without trans-sphenoidal surgery. Algorithms with primary surgery and secondary somatostatin analogs are 30% cheaper per 100 patients than algorithms with primary somatostatin analogues and secondary surgery. Per 100 patients, algorithms including lanreotide Autogel are 14-34% more expensive than algorithms including octreotide long-acting release. These life-long costs should be taken into consideration when making choices between treatment algorithms.
authors.affiliation: Department of Endocrinology, Leiden University Medical Center, PO Box 9600, 2300 RC Leiden, The Netherlands. nrbiermasz@lumc.nl
authors.forename: Nienke R
authors.initials: NR
authors.lastname: Biermasz
authors.forename: Ferdinand
authors.initials: F
authors.lastname: Roelfsema
authors.forename: Alberto M
authors.initials: AM
authors.lastname: Pereira
authors.forename: Johannes A
authors.initials: JA
authors.lastname: Romijn
mesh_terms: D000172:Acromegaly / Q000188:drug therapy / Q000191:economics* / Q000601:surgery; D000465:Algorithms; D000970:Antineoplastic Agents / Q000008:administration & dosage / Q000191:economics* / Q000627:therapeutic use; D002986:Clinical Trials as Topic; D003692:Delayed-Action Preparations; D005782:Gels; D006801:Humans; D009426:Netherlands / Q000453:epidemiology; D010456:Peptides, Cyclic / Q000008:administration & dosage / Q000191:economics* / Q000627:therapeutic use; D013004:Somatostatin / Q000008:administration & dosage / Q000031:analogs & derivatives* / Q000191:economics / Q000627:therapeutic use; D013997:Time Factors; D016896:Treatment Outcome
chemical_list: D000970:Antineoplastic Agents; D003692:Delayed-Action Preparations; D005782:Gels; D010456:Peptides, Cyclic; C060347:lanreotide; D013004:Somatostatin